8-K
filed June 12, 2023, 7:59 PM ET
ticker TCRT
CIK 0001107421
other material
confidence high
sentiment neutral
materiality 0.60
Alaunos Therapeutics stockholders approve reverse stock split and increase in authorized shares
Alaunos Therapeutics, Inc.
- Stockholders approved a reverse stock split at a ratio of 1-for-5 to 1-for-15, at Board discretion (141.4M for, 38.5M against).
- Authorized common shares increased from 420M to 520M (138.3M for, 41.9M against).
- All seven director nominees elected; RSM US LLP ratified as independent auditor for FY2023 (165.4M for).
- Advisory say-on-pay approved (85.9M for); one-year frequency selected for future advisory votes (94.4M for).
Key facts
Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Alaunos Therapeutics, Inc.: Increased authorized shares of common stock from 420,000,000 to 520,000,000 (effective 2023-06-12).
- Change
- charter amendment
- Effective
- 2023-06-12
Exact text from the filing
the Company’s stockholders voted on and approved an amendment (the “Amendment”) to the Company’s Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”) to increase the number of authorized shares of common stock from 420,000,000 shares to 520,000,000 shares.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Alaunos Therapeutics, Inc. shareholders approved Advisory vote on executive compensation at the 2023-06-06 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-06-06
Exact text from the filing
For Against Abstain Broker Non-Votes 85,893,572 20,980,848 1,948,700 72,019,091
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Alaunos Therapeutics, Inc. shareholders approved Approval of amendment and restatement of Certificate of Incorporation to effect a reverse stock split at ratio between 1-for-5 and 1-for-15 at the 2023-06-06 meeting.
- Proposal
- reverse split
- Outcome
- passed
- Meeting
- 2023-06-06
Exact text from the filing
For Against Abstain Broker Non-Votes 141,445,911 38,471,417 924,883 —
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Alaunos Therapeutics, Inc. shareholders approved Adjournment proposal to permit further solicitation if needed for Proposals 5 and 6 at the 2023-06-06 meeting.
- Outcome
- passed
- Meeting
- 2023-06-06
Exact text from the filing
For Against Abstain Broker Non-Votes 144,264,709 34,642,989 1,934,513 —
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Alaunos Therapeutics, Inc. shareholders approved Approval of amendment to Certificate of Incorporation to increase authorized shares of common stock from 420,000,000 to 520,000,000 at the 2023-06-06 meeting.
- Proposal
- charter amendment
- Outcome
- passed
- Meeting
- 2023-06-06
Exact text from the filing
Proposal 6 - Approval of Amendment of the Certificate of Incorporation
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Alaunos Therapeutics, Inc. shareholders approved Ratification of RSM US LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-06 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-06
Exact text from the filing
For Against Abstain Broker Non-Votes 165,357,175 14,209,546 1,275,490 —
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Alaunos Therapeutics, Inc. shareholders approved Election of Directors at the 2023-06-06 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-06
Exact text from the filing
Proposal 1 - Election of Directors The Company’s stockholders elected all seven persons listed below as directors
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Alaunos Therapeutics, Inc. shareholders voted on Advisory vote on frequency of say-on-pay votes at the 2023-06-06 meeting.
- Proposal
- say on pay frequency
- Meeting
- 2023-06-06
Exact text from the filing
One Year Two Years Three Years Abstain 94,445,383 776,719 3,126,416 10,474,602
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.